Compare iShares Global Tech ETF (IXN) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Global Tech ETF vs Repligen Corporation Common Stock — how do they compare? iShares Global Tech ETF trades at $141 (market cap $9.41B), while Repligen Corporation Common Stock trades at $178.85 (market cap $11.31B). The key difference: Repligen Corporation Common Stock is the larger of the two by market cap, and iShares Global Tech ETF is more actively traded (655,816 versus 1,216,919). Which is the better fit depends on your goals — on Pluang, investors hold iShares Global Tech ETF for 48 Days and Repligen Corporation Common Stock for 0 Days on average.
| IXN | RGEN | |
|---|---|---|
Market Cap | $9.41B | $11.31B |
Volume | 655,816 | 1,216,919 |
Sector | Sector/Thematic | Health |
52-Week High | $152.94 | $194.57 |
52-Week Low | $95.76 | $102.87 |
Typical Hold Time | 48 Days | 0 Days |
Enterprise Value | — | $11.20B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IXN (iShares Global Tech ETF) trades at $147.07, down 0.49% on the day but maintains a bullish technical signal with strong moving average support. The ETF recently hit a 52-week high, reflecting momentum despite current consolidation. Technical indicators show mixed signals with neutral RSI readings but bearish ADX trends, while support levels cluster around $146-147.
The outlook remains constructive given the ETF's exposure to global technology leaders and attractive valuation metrics. Key risks include concentration in tech stocks and AI sector volatility. Analyst sentiment appears positive with recent buy ratings citing compelling valuations and long-term growth potential in the global tech landscape.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Global Tech ETF
IXN provides exposure to global electronics, software, and hardware companies. It tracks the S&P Global 1200 Information Technology Index, covering tech leaders across both developed and emerging markets.
Read more on IXN →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
